TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1532-1827
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours ; volume:122 ; number:5 ; day:20 ; month:12 ; year:2019 ; pages:658-667 ; date:3.2020
British journal of cancer ; 122, Heft 5 (20.12.2019), 658-667, 3.2020
- Urheber
-
Saito, Yurina
Takahashi, Tsuyoshi
Obata, Yuuki
Nishida, Toshirou
Ohkubo, Shuichi
Nakagawa, Fumio
Serada, Satoshi
Fujimoto, Minoru
Ohkawara, Tomoharu
Nishigaki, Takahiko
Sugase, Takahito
Koh, Masahiro
Ishida, Tomo
Tanaka, Koji
Miyazaki, Yasuhiro
Makino, Tomoki
Kurokawa, Yukinori
Nakajima, Kiyokazu
Yamasaki, Makoto
Hirota, Seiichi
Naka, Tetsuji
Mori, Masaki
Doki, Yuichiro
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41416-019-0688-y
- URN
-
urn:nbn:de:101:1-2021012517471577425706
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 05:31 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Saito, Yurina
- Takahashi, Tsuyoshi
- Obata, Yuuki
- Nishida, Toshirou
- Ohkubo, Shuichi
- Nakagawa, Fumio
- Serada, Satoshi
- Fujimoto, Minoru
- Ohkawara, Tomoharu
- Nishigaki, Takahiko
- Sugase, Takahito
- Koh, Masahiro
- Ishida, Tomo
- Tanaka, Koji
- Miyazaki, Yasuhiro
- Makino, Tomoki
- Kurokawa, Yukinori
- Nakajima, Kiyokazu
- Yamasaki, Makoto
- Hirota, Seiichi
- Naka, Tetsuji
- Mori, Masaki
- Doki, Yuichiro
- SpringerLink (Online service)
Ähnliche Objekte (12)
Reintroduction of Imatinib in GIST
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
Imatinib Mesylate in Chronic Myeloid Leukemia
Successful Treatment of Imatinib-Induced DRESS Syndrome Using Reslizumab without Cessation of Imatinib: A Case Report
Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors
Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
Erratum to: Exploiting the promiscuity of imatinib
Mutationsanalyse von Tyrosinkinasen bei Imatinib-sensiblen Weichteilsarkomen
Imatinib in India: Is the efficacy universal?
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
Einfluss von Imatinib und Rituximab auf immunkompetente Zellen
A Rare Adverse Drug Reaction of Imatinib Mesylate
Reintroduction of Imatinib in GIST
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
Imatinib Mesylate in Chronic Myeloid Leukemia
Successful Treatment of Imatinib-Induced DRESS Syndrome Using Reslizumab without Cessation of Imatinib: A Case Report
Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors
Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
Erratum to: Exploiting the promiscuity of imatinib
Mutationsanalyse von Tyrosinkinasen bei Imatinib-sensiblen Weichteilsarkomen
Imatinib in India: Is the efficacy universal?
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
Einfluss von Imatinib und Rituximab auf immunkompetente Zellen
A Rare Adverse Drug Reaction of Imatinib Mesylate
Reintroduction of Imatinib in GIST
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
Imatinib Mesylate in Chronic Myeloid Leukemia
Successful Treatment of Imatinib-Induced DRESS Syndrome Using Reslizumab without Cessation of Imatinib: A Case Report
Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors
Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
Erratum to: Exploiting the promiscuity of imatinib
Mutationsanalyse von Tyrosinkinasen bei Imatinib-sensiblen Weichteilsarkomen
Imatinib in India: Is the efficacy universal?
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
Einfluss von Imatinib und Rituximab auf immunkompetente Zellen